Short Interest Change: A Reversal for Ampio Pharmaceuticals Incorporated (NYSEMKT:AMPE) Is Near. The Stock Has Decrease in Shorts

November 24, 2016 - By Louis Casey   ·   0 Comments

Short Interest Change: A Reversal for Ampio Pharmaceuticals Incorporated (NYSEMKT:AMPE) Is Near. The Stock Has Decrease in Shorts

The stock of Ampio Pharmaceuticals Incorporated (NYSEMKT:AMPE) registered a decrease of 2.31% in short interest. AMPE’s total short interest was 5.38M shares in November as published by FINRA. Its down 2.31% from 5.51 million shares, reported previously. With 196,100 shares average volume, it will take short sellers 27 days to cover their AMPE’s short positions. The short interest to Ampio Pharmaceuticals Incorporated’s float is 14.1%. The stock increased 0.07% or $0.001 on November 23, hitting $0.73. About 76,604 shares traded hands. Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) has declined 82.02% since April 22, 2016 and is downtrending. It has underperformed by 87.43% the S&P500.

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $41.91 million. The Firm is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. It currently has negative earnings. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.

Insitutional Activity: The institutional sentiment decreased to 0.91 in 2016 Q2. Its down 1.21, from 2.12 in 2016Q1. The ratio worsened, as 6 funds sold all Ampio Pharmaceuticals Inc shares owned while 11 reduced positions. 16 funds bought stakes while 20 increased positions. They now own 11.72 million shares or 32.69% more from 8.83 million shares in 2016Q1.
Citigroup Inc last reported 8,426 shares in the company. Group One Trading Limited Partnership reported 136,927 shares or 0% of all its holdings. Moreover, Morgan Stanley has 0% invested in Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) for 31,081 shares. Wells Fargo & Mn has 0% invested in the company for 29,924 shares. Rhumbline Advisers holds 43,421 shares or 0% of its portfolio. Amer Intll last reported 25,291 shares in the company. Federated Pa, a Pennsylvania-based fund reported 242 shares. Moreover, Northern Tru Corporation has 0% invested in Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) for 481,779 shares. Ny State Common Retirement Fund owns 44,900 shares or 0% of their US portfolio. Millennium Mgmt Limited last reported 17,465 shares in the company. Blackrock Advisors Ltd Limited Liability Company reported 22,026 shares or 0% of all its holdings. Brown Advisory Inc accumulated 0% or 16,700 shares. Concannon Wealth Mngmt Ltd Liability owns 4,000 shares or 0.01% of their US portfolio. The Ontario – Canada-based Royal State Bank Of Canada has invested 0% in Ampio Pharmaceuticals Inc (NYSEMKT:AMPE). Knoll Capital Management L P owns 3.24 million shares or 1.35% of their US portfolio.

AMPE Company Profile

Ampio Pharmaceuticals, Inc., incorporated on March 24, 2010, is a biopharmaceutical company. The Firm is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema (DME). The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Firm is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.

More important recent Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on April 18, 2011, also Prnewswire.com published article titled: “Ampio Reports Peer-Reviewed Publication on the Potential use of Ampionâ„¢ in …”, Thestreet.com published: “Ampio Pharmaceuticals (AMPE) Stock Tanks Today after Treatment Fails To Reach …” on April 20, 2015. More interesting news about Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) was released by: Quotes.Wsj.com and their article: “News Ampio Pharmaceuticals Inc.AMPE” with publication date: May 20, 2011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>